MedPath

EQUIC-CC: Enhancing Quality of Informed Consent - Customized Consent

Completed
Conditions
Healthy
Registration Number
NCT00032539
Lead Sponsor
US Department of Veterans Affairs
Brief Summary

Patients in 'parent' cooperative study projects are interviewed about their experiences in the informed consent process.

Detailed Description

Intervention: (1) Cognitive stratification (obtained by a test of cognitive ability, followed by a tailored IC process); (2) Pre-recruitment video (a patient-activation video designed to prevent several common misconceptions; (3) Provide prospective research volunteers with a sense of the purpose and methods of controlled research); and (4) Evaluation of the informed consent process using the Brief Informed Consent Evaluation Protocol (BICEP) developed in EQUIC-DP.

Primary Hypothesis: The validity of informed consent can be improved, as measured by an independent interview of patients (BICEP), by at least one of three interventions described above.

Primary Outcomes: The quality of the informed consent process, as measured by the BICEP (Brief Informed Consent Evaluation Protocol). The BICEP also offers a method to certify informed consent in routine use.

Study Abstract: Customized Consent will develop and test an innovative, supplemental method of disclosing information to patients in the informed consent process. This disclosure strategy is intended to increase patients' understanding and satisfaction with the consent process. This study has two goals:

* to evaluate the effectiveness of an intervention to improve comprehension during informed consent; and

* to identify those patients for whom this intervention is most effective.

The primary goal of EQUIC-CC is to determine whether an intervention, added to usual procedures for obtaining informed consent, is able to improve comprehension. The second goal of EQUIC-CC is to identify those patients for whom an augmented consent intervention is most effective, as well as to determine which subgroups of patients, if any, are most likely to benefit from visual information added to the usual disclosure phase of obtaining informed consent.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria

Inclusion Criteria:

  • Depends on 'parent' study
Exclusion Criteria

Exclusion Criteria:

  • Depends on 'parent' study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
improve method of disclosing information to patients in the informed consent processpost-randomization
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

VA Medical Center, Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

VA Medical Center, Durham

🇺🇸

Durham, North Carolina, United States

Stanford University

🇺🇸

Stanford, California, United States

VA Palo Alto Health Care System

🇺🇸

Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath